



Toxicological Profile for 1,2-Dibromo-3-Chloropropane

April 2018



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
April 2018	Update of data in Chapters 2, 3, and 7
September 1992	Final Toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Rae T. Benedict, Ph.D.

David W. Wohlers, Ph.D.

ATSDR, Division of Toxicology and Human Health
Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice.

CONTENTS

FOREWORD	ii
VERSION HISTORY	iv
CONTRIBUTORS & REVIEWERS	v
CONTENTS.....	vi
LIST OF FIGURES	viii
LIST OF TABLES	ix
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	1
1.3 MINIMAL RISK LEVELS (MRLs)	4
CHAPTER 2. HEALTH EFFECTS.....	7
2.1 INTRODUCTION.....	7
2.2 DEATH	36
2.3 BODY WEIGHT.....	36
2.4 RESPIRATORY	37
2.5 CARDIOVASCULAR.....	37
2.6 GASTROINTESTINAL.....	37
2.7 HEMATOLOGICAL	38
2.8 MUSCULOSKELETAL	39
2.9 HEPATIC.....	39
2.10 RENAL	40
2.11 DERMAL.....	41
2.12 OCULAR	41
2.13 ENDOCRINE.....	41
2.14 IMMUNOLOGICAL	42
2.15 NEUROLOGICAL.....	42
2.16 REPRODUCTIVE	43
2.17 DEVELOPMENTAL.....	46
2.18 OTHER NONCANCER.....	47
2.19 CANCER.....	47
2.20 GENOTOXICITY	49
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	54
3.1 TOXICOKINETICS.....	54
3.1.1 Absorption.....	54
3.1.2 Distribution.....	54
3.1.3 Metabolism.....	55
3.1.4 Excretion	57
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	57
3.1.6 Animal-to-Human Extrapolations	58
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	58
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	59
3.3.1 Biomarkers of Exposure.....	60
3.3.2 Biomarkers of Effect	61
3.4 INTERACTIONS WITH OTHER CHEMICALS	61

CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	62
4.1 CHEMICAL IDENTITY	62
4.2 PHYSICAL AND CHEMICAL PROPERTIES	62
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE	64
5.1 OVERVIEW	64
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	65
5.2.1 Production	65
5.2.2 Import/Export	66
5.2.3 Use	66
5.2.4 Disposal	66
5.3 RELEASES TO THE ENVIRONMENT	67
5.3.1 Air	67
5.3.2 Water	68
5.3.3 Soil	68
5.4 ENVIRONMENTAL FATE	68
5.4.1 Transport and Partitioning	68
5.4.2 Transformation and Degradation	71
5.5 LEVELS IN THE ENVIRONMENT	72
5.5.1 Air	73
5.5.2 Water	74
5.5.3 Sediment and Soil	76
5.5.4 Other Media	77
5.6 GENERAL POPULATION EXPOSURE	78
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	78
CHAPTER 6. ADEQUACY OF THE DATABASE	80
6.1 Information on Health Effects	80
6.2 Identification of Data Needs	82
6.3 Ongoing Studies	90
CHAPTER 7. REGULATIONS AND GUIDELINES	91
CHAPTER 8. REFERENCES	93
APPENDICES	
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR 1,2-DIBROMO- 3-CHLOROPROPANE	B-1
APPENDIX C. USER'S GUIDE	C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E. GLOSSARY	E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to 1,2-Dibromo-3-Chloropropane.....	2
1-2. Health Effects Found in Animals Following Oral Exposure to 1,2-Dibromo-3-Chloropropane.....	3
1-3. Summary of Sensitive Targets of 1,2-Dibromo-3-Chloropropane -- Inhalation	4
1-4. Summary of Sensitive Targets of 1,2-Dibromo-3-Chloropropane -- Oral	5
2-1. Overview of the Number of Studies Examining 1,2-Dibromo-3-Chloropropane Health Effects	10
2-2. Levels of Significant Exposure to 1,2-Dibromo-3-Chloropropane – Inhalation	18
2-3. Levels of Significant Exposure to 1,2-Dibromo-3-Chloropropane – Oral	31
3-1. The Metabolism of 1,2-Dibromo-3-chloropropane in Rats	56
5-1. Number of NPL Sites with 1,2-Dibromo-3-chloropropane Contamination	64
6-1. Summary of Existing Health Effects Studies on 1,2-Dibromo-3-Chloropropane By Route and Endpoint	81

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 1,2-Dibromo-3-Chloropropane.....	6
2-1. Levels of Significant Exposure to 1,2-Dibromo-3-Chloropropane – Inhalation	11
2-2. Levels of Significant Exposure to 1,2-Dibromo-3-Chloropropane – Oral	22
2-3. Levels of Significant Exposure to 1,2-Dibromo-3-Chloropropane – Dermal	35
2-4. Genotoxicity of 1,2-Dibromo-3-Chloropropane <i>In Vivo</i>	49
2-5. Genotoxicity of 1,2-Dibromo-3-Chloropropane <i>In Vitro</i>	51
4-1. Chemical Identity of 1,2-Dibromo-3-Chloropropane	62
4-2. Physical and Chemical Properties of 1,2-Dibromo-3-Chloropropane.....	62
5-1. Facilities that Produce, Process, or Use 1,2-Dibromo-3-Chloropropane.....	65
5-2. Releases to the Environment from Facilities that Produce, Process, or Use 1,2-Dibromo-3-Chloropropane.....	67
5-3. Lowest Limit of Detection Based on Standards	72
5-4. 1,2-Dibromo-3-Chloropropane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	73
5-5. Levels of 1,2-Dibromo-3-chloropropane in Potable Water	75
7-1. Regulations and Guidelines Applicable to 1,2-Dibromo-3-Chloropropane	91